S1PR1 and ulcerative colitis: In the latest phase 3 drug trial, etrasimod (S1PR1, 4, and 5) was used as an S1P receptor modulator for treating immune-mediated diseases, including ulcerative colitis, confirming the efficacy of etrasimod as induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis (149).